The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Which patients should be considered for allo-HSCT?
Jeffrey Lancet
Gert Ossenkoppele
Charles Craddock
Roland Walter
Jorge Sierra
Gail J. RobozDuring the AML Hub Steering Committee meeting, held on November 15, 2023, key opinion leaders met to discuss which patients should be considered for allogenic hematopoietic stem cell transplantation. This discussion was chaired by Charles Craddock and featured Jefferey Lancet, Roland Walter, Jorge Sierra, Gail Roboz, and Gert Ossenkoppele.
Which patients should be considered for allo-HSCT?
Charles Craddock discussed the optimization of transplant outcomes and highlighted key data from several recent studies. The steering committee considered factors that may impact transplant outcomes and the need to optimize patient status before transplant. They also discussed treatment decisions in older/unfit patients and explored factors to consider when deciding whether to proceed to transplant or pursue ongoing maintenance therapy.